AIM: Previous studies have shown transient decreases in heart rate (HR) following administration of sphingosine 1-phosphate (S1P) receptor modulators including BAF312. This study was conducted to determine whether dose titration of BAF312 reduces or eliminates these effects. METHODS:Fifty-six healthy subjects were randomized 1:1:1:1 to receive BAF312 in one of two dose titration (DT) regimens (DT1 and DT2: 0.25-10 mg over 9-10 days), no titration (10 mg starting dose) or placebo. Pharmacodynamic and pharmacokinetic parameters were assessed. RESULTS: Neither DT1 nor DT2 resulted in clinically significant bradycardia or atrioventricular conduction effects. Both titration regimens showed a favourable difference on each of days 1-12 vs. the non-titration regimen on day 1 for HR effects (P < 0.0001). On day 1, the geometric mean ratio of the fraction from the previous day in minimum daily HR between DT1 and non-titration was 1.18 (95% confidence interval [CI] 1.13, 1.23) and 1.14 (95% CI 1.09, 1.18) for DT2 (both P < 0.05) with significant differences noted through to day 12. Non-titration HRs showed considerable separation from placebo throughout the study. There was no statistically significant reduction in HR vs. placebo on day 1 in either titration regimen. On days 3-7 subjects in DT1 and DT2 experienced minor reductions in HR vs. placebo (approximately 5 beats min⁻¹; P ≤ 0.0001). From days 9-12, HRs in both titration regimens were comparable with placebo. CONCLUSION: Both titration regimens effectively attenuated the initial bradyarrhythmia observed on day 1 of treatment with BAF312 10 mg.
RCT Entities:
AIM: Previous studies have shown transient decreases in heart rate (HR) following administration of sphingosine 1-phosphate (S1P) receptor modulators including BAF312. This study was conducted to determine whether dose titration of BAF312 reduces or eliminates these effects. METHODS: Fifty-six healthy subjects were randomized 1:1:1:1 to receive BAF312 in one of two dose titration (DT) regimens (DT1 and DT2: 0.25-10 mg over 9-10 days), no titration (10 mg starting dose) or placebo. Pharmacodynamic and pharmacokinetic parameters were assessed. RESULTS: Neither DT1 nor DT2 resulted in clinically significant bradycardia or atrioventricular conduction effects. Both titration regimens showed a favourable difference on each of days 1-12 vs. the non-titration regimen on day 1 for HR effects (P < 0.0001). On day 1, the geometric mean ratio of the fraction from the previous day in minimum daily HR between DT1 and non-titration was 1.18 (95% confidence interval [CI] 1.13, 1.23) and 1.14 (95% CI 1.09, 1.18) for DT2 (both P < 0.05) with significant differences noted through to day 12. Non-titration HRs showed considerable separation from placebo throughout the study. There was no statistically significant reduction in HR vs. placebo on day 1 in either titration regimen. On days 3-7 subjects in DT1 and DT2 experienced minor reductions in HR vs. placebo (approximately 5 beats min⁻¹; P ≤ 0.0001). From days 9-12, HRs in both titration regimens were comparable with placebo. CONCLUSION: Both titration regimens effectively attenuated the initial bradyarrhythmia observed on day 1 of treatment with BAF312 10 mg.
Authors: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694
Authors: Robert Schmouder; Denise Serra; Yibin Wang; John M Kovarik; John DiMarco; Thomas L Hunt; Marie-Claude Bastien Journal: J Clin Pharmacol Date: 2006-08 Impact factor: 3.126
Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Krzysztof Selmaj; David K B Li; Hans-Peter Hartung; Bernhard Hemmer; Ludwig Kappos; Mark S Freedman; Olaf Stüve; Peter Rieckmann; Xavier Montalban; Tjalf Ziemssen; Lixin Zhang Auberson; Harald Pohlmann; Francois Mercier; Frank Dahlke; Erik Wallström Journal: Lancet Neurol Date: 2013-06-11 Impact factor: 44.182
Authors: T G Murali Dhar; Hai-Yun Xiao; Jenny Xie; Lois D Lehman-McKeeman; Dauh-Rurng Wu; Marta Dabros; Xiaoxia Yang; Tracy L Taylor; Xia D Zhou; Elizabeth M Heimrich; Rochelle Thomas; Kim W McIntyre; Bethanne Warrack; Hong Shi; Paul C Levesque; Jia L Zhu; James Hennan; Praveen Balimane; Zheng Yang; Anthony M Marino; Georgia Cornelius; Celia J D'Arienzo; Arvind Mathur; Ding Ren Shen; Mary Ellen Cvijic; Luisa Salter-Cid; Joel C Barrish; Percy H Carter; Alaric J Dyckman Journal: ACS Med Chem Lett Date: 2016-01-19 Impact factor: 4.345
Authors: M Germana Sanna; Kevin P Vincent; Emanuela Repetto; Nhan Nguyen; Steven J Brown; Lusine Abgaryan; Sean W Riley; Nora B Leaf; Stuart M Cahalan; William B Kiosses; Yasushi Kohno; Joan Heller Brown; Andrew D McCulloch; Hugh Rosen; Pedro J Gonzalez-Cabrera Journal: Mol Pharmacol Date: 2015-10-22 Impact factor: 4.436
Authors: Juan S Lasa; Pablo A Olivera; Stefanos Bonovas; Silvio Danese; Laurent Peyrin-Biroulet Journal: Drug Saf Date: 2021-03-05 Impact factor: 5.606
Authors: Tomohiko Harada; Darren Wilbraham; Guillemette de La Borderie; Shinsuke Inoue; Jim Bush; A John Camm Journal: Br J Clin Pharmacol Date: 2017-01-19 Impact factor: 4.335
Authors: Jonathan Q Tran; Jeffrey P Hartung; Allan D Olson; Boaz Mendzelevski; Gregg A Timony; Marcus F Boehm; Robert J Peach; Sheila Gujrathi; Paul A Frohna Journal: Clin Pharmacol Drug Dev Date: 2017-08-07